Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company whose news flow centers on its NMDA-based drug pipeline and interventional psychiatry operations. Company announcements frequently highlight progress with NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral D-cycloserine/lurasidone combination, both aimed at serious central nervous system disorders such as suicidal depression and suicidal bipolar depression.
Investors following NRXP news can expect updates on FDA interactions, including Fast Track and Breakthrough Therapy designations, Abbreviated New Drug Application (ANDA) milestones for preservative-free ketamine, and New Drug Application (NDA) activities. The company also reports on the use of large Real World Evidence datasets to support potential Accelerated Approval pathways for NRX-100 in suicidal ideation associated with depression and bipolar depression.
Another recurring theme in NRx Pharmaceuticals’ news is the expansion of its HOPE Therapeutics subsidiary, which operates interventional psychiatry clinics. Releases describe clinic acquisitions, strategic interests in practices, and deployment of treatments such as ketamine-based therapies, Transcranial Magnetic Stimulation (TMS), Hyperbaric Oxygen Therapy, and digital therapeutics for suicidal depression, PTSD, and related conditions. Updates often cover new treatment protocols that combine TMS with D-cycloserine and other medications.
NRXP news items also include corporate developments such as conference presentations, corporate update calls, financing transactions, and changes in independent registered public accounting firms, as reflected in SEC filings. For investors and observers, the news stream provides ongoing insight into NRx Pharmaceuticals’ clinical progress, regulatory steps, clinic network growth, and capital markets activity related to its focus on Neuroplastic Therapies and suicidal depression.
NRx Pharmaceuticals (Nasdaq: NRXP) will hold its 2025 annual meeting of stockholders on March 23, 2026 at 10:00 a.m. ET in a virtual-only format at https://www.cstproxy.com/nrxpharma/2026. The Board set a record date of February 12, 2026 for stockholders entitled to notice and to vote. The company said its proxy statement, to be filed with the SEC prior to the meeting, will describe meeting matters and voting procedures.
Because the meeting date is more than 60 days after the prior meeting anniversary, the advance-notice deadline under the bylaws for stockholder proposals and director nominations (other than Rule 14a-8 submissions) is the close of business on January 26, 2026. Submissions must follow the bylaws and be delivered by hand, overnight courier, or certified/registered mail to the company’s principal executive offices.
Bright Mountain Media (OTCQB: BMTM) released an on-demand webinar, “How Connected Research Helped Aruba Reimagine Tourism Marketing,” detailing a sub-30-minute case study of Aruba Tourism Authority, Big Village, and Deep Focus. The campaign shifted messaging to attitudinal segments, linked media activations to CRM, and reportedly delivered record visitation and improved marketing ROI. The campaign won a Gold Magellan Award and Shorty Impact recognition. The company also disclosed CEO Matt Drinkwater purchased 299,500 shares on December 10, 2025 (Form 5 filed).
NRx Pharmaceuticals (Nasdaq: NRXP) will submit real-world evidence from over 70,000 patients treated with intravenous ketamine or nasal S-ketamine to the FDA to support an Accelerated Approval application for NRX-100 (preservative-free ketamine) under Fast Track designation for treatment of suicidal ideation in depression, including bipolar depression.
The RWE, supplied by Osmind, includes nearly 1 million treatment sessions, continuous vitals, safety elements, and a prior 20,000-patient analysis showing rapid resolution of depression and suicidality.
NRx Pharmaceuticals (Nasdaq: NRXP) and neurocare Group AG announced a partnership to create a nationwide network of clinics delivering integrated neuroplastic therapy for Depression, PTSD, and other CNS disorders.
The program will combine TMS, ketamine and other neuroplastic drugs, hyperbaric oxygen, psychotherapy, telepsychiatry, and shared training; partners cite published results showing 87% response and 72% remission in treatment‑resistant depression and a pilot showing high remission rates in first responders. The partners plan to leverage > 400 Apollo® TMS devices, ~20 US clinics, and aim for driving‑distance access across the US by year‑end 2026, while exploring clinical trials for additional indications.
NRx Pharmaceuticals (Nasdaq: NRXP) said it eliminated its remaining balance sheet debt after converting the final $5.4 million owed to Anson Funds into common stock with no warrants or repricing provisions.
The company noted Anson originally lent $16.2 million to fund prior loans and operating expenses and that it expects to end Dec 31, 2025 with a debt-free balance sheet. Management said the debt-free capital structure positions the company for potential drug approvals and clinic expansions in 2026.
NRx Pharmaceuticals (Nasdaq: NRXP) amended its Investigational New Drug filing for NRX-101 (D-cycloserine/lurasidone) to add use in combination with Transcranial Magnetic Stimulation (TMS) for treatment of depression, including suicidal depression, and will offer the protocol via clinical trial and Expanded Access.
Company holds >25,000 investigational doses, cites prior studies reporting 75% response/40% remission (Cole et al.) and real-world data with 87% response/72% remission at 6 weeks after a single-day TMS+DCS regimen, and says NRX-101 has composition-of-matter patents and Breakthrough Therapy designation.
NRx Pharmaceuticals (NASDAQ: NRXP) announced the FDA has received and deemed substantially complete its Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV ketamine. The FDA assigned a GDUFA goal date of July 29, 2026 for final review. NRx manufactured initial registration lots, can scale to 1 million vials per month, and seeks KETAFREE™ as a proprietary name. The company estimates the current worldwide generic ketamine market at $750 million per year and is awaiting an FDA response to an August citizen petition about Benzethonium Chloride removal. KETAFREE™ is separate from NRx’s NRX-100 program.
NRx Pharmaceuticals (NASDAQ: NRXP) will host a corporate update conference call on Tuesday, December 2, 2025 at 9:00 AM ET.
The call will cover recent clinical, regulatory, and operational developments. A live webcast will be available at https://ir.nrxpharma.com/events. Domestic participants can dial 1-800-717-1738 and international participants can dial 1-646-307-1865 to join by telephone.
NRx Pharmaceuticals (NASDAQ: NRXP) announced that Founder, Chairman, and CEO Jonathan Javitt, M.D., M.P.H. will present at NobleCon21 (Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference) on Wednesday, December 3, 2025 at 4:30 PM ET in Boca Raton, FL.
The presentation will update the company’s expanded focus and progress across investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions. The company noted it has begun generating clinical revenue and advanced drug development since NobleCon 2024.
Interested parties can register using discount code NRXPNOBLECON. A high-definition webcast will be posted the following day and archived for 90 days on the company site and on NobleCon and Channelchek.
NRx Pharmaceuticals (NASDAQ:NRXP) reported third quarter 2025 results and a corporate update on November 17, 2025. The company reported a $4.0 million loss from operations in Q3 2025 versus $3.0 million in Q3 2024, and recognized first-quarter revenue of approximately $240,000 from the September 8, 2025 Dura Medical acquisition. Cash and equivalents were $7.1 million as of September 30, 2025 ($10.3 million including a subscription receivable collected in October).
Key development highlights include an ANDA refile for preservative-free ketamine (KETAFREE™) with FDA indicating a Q2 2026 GDUFA date, Fast Track designation for NRX-100, Breakthrough status and NDA progress for NRX-101, real-world data showing doubling of TMS effect with D-cycloserine, and HOPE Therapeutics operating three revenue-generating clinics with plans for six+ by year-end. The company says operating capital is sufficient through July 2026.
FAQ
What is the current stock price of Nrx Pharmaceuticals (NRXP)?
What is the market cap of Nrx Pharmaceuticals (NRXP)?
